roquinimex

structure in first source

Also Known As:

LS 2616; LS-2616; Linomide; N-phenylmethyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxamide; PNU-212616; 3-Quinolinecarboxamide, 1,2-dihydro-4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-

Networked: 124 relevant articles (15 outcomes, 31 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Hydroxyquinolines: 9
        roquinimex: 124

Experts

1.	Hedlund, G: 7 articles (11/2003 - 10/2000)
2.	Hedlund, Gunnar: 3 articles (12/2004 - 02/2002)
3.	Thorlacius, H: 3 articles (11/2003 - 11/2000)
4.	Cheng, Jun-Ping: 2 articles (12/2007 - 10/2007)
5.	He, Jun-Feng: 2 articles (12/2007 - 10/2007)
6.	Xiao, Zhi-Yong: 2 articles (12/2007 - 10/2007)
7.	Yang, Ri-Fang: 2 articles (12/2007 - 10/2007)
8.	Yun, Liu-Hong: 2 articles (12/2007 - 10/2007)
9.	Zhang, Yong-Xiang: 2 articles (12/2007 - 10/2007)
10.	Zhou, Wen-Xia: 2 articles (12/2007 - 10/2007)

Related Diseases

1.	Neoplasms (Cancer) 11/01/1999 - "In vivo nuclear magnetic resonance analysis of tumor blood flow in linomide-treated animals showed localization of blood vessels almost exclusively to the periphery of the poorly vascularized tumors with a significant reduction of both vascular functionality and vasodilation. " 11/01/1999 - "The aim of this study was to ascertain the potential usefulness of the antiangiogenic compound linomide for treatment of von Hippel-Lindau (VHL)-related tumors. " 05/01/1995 - "These studies also demonstrated that linomide does not decrease the attachment, migration, or invasive abilities of metastatic cancer cells. " 05/01/1995 - "To test if this antimetastatic response is due to direct effects of linomide on the metastatic cells themselves as well as an induced effect upon inhibition of tumor angiogenesis, additional studies were performed. " 12/01/2002 - "Although linomide regulates anti-self reactivity in mice with experimental and spontaneous autoimmune disorders, the anti-tumor effects induced by allogeneic donor lymphocytes were not affected. "
2.	Autoimmune Diseases (Autoimmune Disease) 01/01/1997 - "Linomide (quinoline-3-carboxamide), a well tolerated, orally administered compound was recently shown to be effective in the prevention and treatment of several autoimmune diseases in experimental animal models. " 12/01/1986 - "The results obtained suggest that LS-2616 may be useful in the treatment of autoimmune disease in man." 02/01/2003 - "Roquinimex is a modulator of the immune system and has been shown to attenuate induction of several inflammatory and autoimmune diseases. " 07/21/2002 - "Linomide prevents development of autoimmune manifestations in other experimentally induced and spontaneous autoimmune diseases as well, but the mechanism of action is unknown. " 06/01/2001 - "The basic mechanism(s) of action of Linomide in inducing beneficial effects in autoimmune diseases is still elusive. "
3.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 06/01/2001 - "In this review, we describe the efficacy of Linomide for ameliorating the autoimmune process and diabetes in the non-obese diabetic (NOD) model of IDDM when administered at early stages of the disease. " 06/01/2001 - "Subsequent clinical studies have shown that Linomide preserves beta-cell function in individuals with new-onset IDDM. " 06/01/2001 - "Based on these data, Linomide or derivatives thereof might be useful for treatment of human IDDM." 11/01/2003 - "The most promising strategies for prevention of type 1 diabetes seem to be in the categories of immunomodulation (e.g., nondepleting anti-CD3, Diapep, linomide) and/or immunostimulation (e.g., QFA, BCG). " 11/15/1996 - "Oral therapy with linomide protects prediabetic nonobese diabetic (NOD) mice from insulin-dependent diabetes mellitus. "
4.	Body Weight (Weight, Body) 06/01/2000 - "In this study 278 AML patients in remission were randomized to receive Roquinimex 0.2 mg/kg body weight or placebo twice weekly for 2 years following ABMT. " 11/01/1996 - "injection of 1 g/kg body weight glucose: Linomide plus isograft 6.7 +/- 1 mmol/L; Linomide alone 18.7 +/- 6.3 mmol/L; p < 0.0001]. " 10/01/1999 - "As part of a phase III placebo-controlled multicenter study patients were randomized to receive Roquinimex, 0.2 mg/kg body weight, or a placebo twice weekly for a duration of 2 yr following autologous bone marrow transplantation for acute myeloid leukemia in remission. "
5.	Prostatic Neoplasms (Prostate Cancer) 08/01/1996 - "treatment with Linomide has antiangiogenic abilities against a series of rat and human prostatic cancer xenografts growing in vivo. " 04/01/1995 - "To test if natural killer (NK) cells might be one of the additional host factors required for the in vivo abilities of linomide, prostatic cancer bearing rats were treated with appropriate antiserum to deplete NK cells and then tested for their response to linomide treatment. " 04/01/1995 - "Treatment of rats with linomide decreases significantly (P < 0.05), by more than 50%, the number of tumor associated macrophages within both locally invasive (i.e., from 20-40 to 10 macrophages/high power field) and highly metastatic primary prostatic cancers (i.e., from 60-70 to 15-37 macrophages/high power field). " 06/01/1992 - "These results suggest that the requirement for host involvement in the antitumor effects of linomide against rat prostatic cancers may involve both immune and nonimmune host mechanism(s) (e.g., antiangiogenesis)." 06/01/1992 - "Likewise, the antitumor effects of linomide are also produced in prostatic cancer-bearing athymic nude rats. "

Related Drugs and Biologics

1.	Immunologic Factors (Immunomodulators)
2.	roquinimex
3.	Angiogenesis Inhibitors
4.	Interleukin-2 (IL2)
5.	Cytokines
6.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
7.	Androgens
8.	Intravenous Immunoglobulins (IVIG)
9.	Monoclonal Antibodies
10.	Drinking Water

Related Therapies and Procedures

1.	Therapeutics
2.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
3.	Immunotherapy
4.	Photopheresis
5.	Immunomodulation